Accuray(US:ARAY)2024-08-14 20:41Financial Performance Highlights - Accuray achieved record system shipments with a 24% increase compared to the same period in the prior fiscal year, resulting in the highest revenue quarter in company history[14] - Gross orders grew by 10% in FY24, reaching $342.1 million, with a book-to-bill ratio of 1.5, indicating strong demand[22] - International markets experienced a 10% annual revenue growth, driven by the patient access strategy in emerging markets[22] - Operating expenses decreased by 6% annually to $142.4 million, driven by disciplined cost control[22] - Adjusted EBITDA for Q4'FY24 increased by 94% to $10.1 million[22] Product and Market Expansion - The Accuray Precision® Treatment Planning System (TPS) gained approval in China for use with the Tomo® C radiation therapy system for the Type B market[15] - First installations of the VitalHold surface-guided radiation therapy (SGRT) on the Radixact® System were implemented in Japan[16] - The Accuray Helix, a configuration of the Radixact® Treatment Delivery System, gained CE Mark for use in India and other high potential markets[17] FY25 Guidance - The company projects FY25 revenue to be in the range of $460 million to $470 million, representing a growth of 3% to 5%[24] - Adjusted EBITDA for FY25 is projected to be between $27.5 million and $29.5 million, indicating a growth of 40% to 50%[24]